Effect of Anti-β2Glycoprotein I Lupus Anticoagulants on Fibrin Polymerization and Fibrinolysis

References

• Hughes G. R.V. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. BMJ 1983; 287: 1088–9
   PubMed Web of Science ®Google Scholar
• Harris E. N. Syndrome of the Black swan. Br. J. Rheumatol. 1987; 26: 324–6
   PubMedGoogle Scholar
• Ashcrson R. A 'primary' antiphospholipid syndrome. J. Rheumatol 1988; 15: 1742–4
   PubMedGoogle Scholar
• Gharavi A. E., Wilson W. A. The syndrome of thrombosis, thrombocytopenia, and recurrent spontaneous abortions associated with antiphospholipid antibodies: the Hughes syndrome. Lupus 1996; 5: 343–4
   PubMedGoogle Scholar
• Hughes G. V.R. Hughes' syndrome: the antiphospholipid syndrome. A historical view. Lupus 1998; 7(Suppl. 2)SI–4
   Google Scholar
• Roubey R. A.S. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum. 1996; 39: 1444–54
   PubMed Web of Science ®Google Scholar
• Cabiedes J., Cabral A. R., Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erithematosus associate more strongly with anti-βGlycoprotein-l than with antiphospholipid antibodies. J. Rheumatol 1995; 22: 1899–906
   PubMed Web of Science ®Google Scholar
• Balestrieri G., Tincani A., Spatola L., Allegri F., Prati E., Cattaneo R., Valesini G., Del Papa N., Meroni P. Anti-β2-Glycoprotcin-I antibodies: a marker of antiphospholipid syndrome?. Lupus 1995; 4: 122–30
   PubMed Web of Science ®Google Scholar
• Martinuzzo M. E, Forastiero R. R., Carrcras L. O. Anti-β2-Glycoprotein-I antibodies detection and association with thrombosis. Br. J. Haematol. 1995; 89: 397–402
   PubMed Web of Science ®Google Scholar
• Roubey R. A.S., Maldonado M. A., Byrd S. N. Comparison of an enzyme-linked immunosorbent assay for antibodies to β2-Glycoprotein-I and a conventional cardiolipin immunoassay. Arthritis Rheum. 1996; 39: 1606–7
   PubMedGoogle Scholar
• Pengo V., Balestrieri G., Tincani A., Spatola L., Biasiolo A., Brocco T. Utilization of dilute Russell's Viper Venom Time to detect autoantibodies against β2-Glycoprotein 1 which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids. Thromh. Haemost. 1997; 77: 123–6
   PubMed Web of Science ®Google Scholar
• Takeya H., Mori T., Gabazza E. C., Kuroda K., Deguchi H., Matsuura E., Ichikawa K., Koike T., Suzuki K. Anti-β2-Glycoprotein I monoclonal antibodies with lupus anticoagulant activity enhance the β2-Glyco-protein I binding to phospholipids. J. Clin. Invest. 1997; 99: 2260
   PubMed Web of Science ®Google Scholar
• Willcms G. M, Janssen M. P, Pelsers M. M.A.L., Comfurius P., Galli M., Zwaal R. F.A., Bevcrs M. Role of divalency in the high-affinity binding of anti-cardiolipin antibody-β2-Glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35(13)833–42
   Google Scholar
• Arnout J., Wittevrongel C, Vanrusselt M., Hoylacrts M., Vermylen J. β2-Glycoprotein I dependent Lupus Anticoagulant forms stable bivalent antibody β2-Glycoprotein I complexes on phospholipid surfaces. Thromh. Haemost. 1998; 79: 79–86
   PubMedGoogle Scholar
• Thiagarajan P., Pengo V., Shapiro S. S. The use of dilute Russell Viper Venom Time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869–73
   PubMed Web of Science ®Google Scholar
• Biasiolo A., Pengo V. Antiphospholipid antibodies are not present in the membrane of gel-filtered platelets of patients with IgG anticardiolipin antibodies, lupus anticoagulant and thrombosis. Blood Cong. Fihrinol. 1993; 4: 425–8
   PubMed Web of Science ®Google Scholar
• Pengo V., Biasiolo A., Brocco T., Tonetto S., Ruffatti A. Autoantibodies to phospholipid binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thonth. Haemost. 1996; 75: 721–4
   PubMedGoogle Scholar
• Tincani A., Spatola L., Prati E., Allegri F., Ferremi P., Cattaneo R., Meroni P., Balestrieri G. The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native bcta2gly-coprotein I and preserved during species' evolution. J. Immunol. 1996; 157: 5732–8
   PubMedGoogle Scholar
• Pengo V., Biasiolo A., Fior M. G. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-Glycoprotein-I is bound to a suitable surface. Thromh. Haemost. 1995; 73: 29–34
   PubMed Web of Science ®Google Scholar
• Mosesson M. W. Fibrinogen and fibrin polymerization: appraisal of the binding events that accompany fibrin generation and fibrin clot assembly. Blood Coag. Fihrinol. 1997; 8: 257–67
   PubMed Web of Science ®Google Scholar
• Hoylaerts M., Rijken D. C, Lijnen H. R., Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J. Biol. Chem. 1982; 257: 2912–9
   PubMed Web of Science ®Google Scholar
• Pengo V., Brocco T., Biasiolo A., Rampazzo P., Carraro P., Zamarchi R. Procoagulant effect of anti-β2Glycoprotein I antibodies with Lupus Anticoagulant activity. Blood 1999; 94: 3814–9
   PubMedGoogle Scholar
• Pengo V., Biasiolo A., Rampazzo P., Brocco T. dRVVT is more sensitive than KCT or TTI for detecting Lupus Anticoagulant activity of anti-β2-Glycoprotein-I autoantibodies. Thromb. Haemost. 1999; 81: 256–8
   PubMed Web of Science ®Google Scholar
• Salemink L., Blezer R., Willems G. M, Galli M., Bevers E., Lindhout T. Antibodies to β2-Glycopro-tcin-I from patients with antiphospholipid syndrome reduce the phospholipid-dependent inhibitory activity of tissue factor pathway inhibitor on factor X activation. Lupus 1998; 7(Suppl. 2)SI80, abstract
   Google Scholar